Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/20048
Title: Development of a rapid functional assay that predicts GLUT1 disease severity.
Authors: Zaman, Sasha M;Mullen, Saul A;Petrovski, Slavé;Maljevic, Snezana;Gazina, Elena V;Phillips, A Marie;Jones, Gabriel Davis;Hildebrand, Michael S;Damiano, John;Auvin, Stéphane;Lerche, Holger;Weber, Yvonne G;Berkovic, Samuel F;Scheffer, Ingrid E;Reid, Christopher A;Petrou, Steven
Affiliation: APHP, Hôpital Robert Debré, Service de Neurologie Pédiatrique, Paris, France
Department of Medicine (RMH) University of Melbourne, Parkville, Australia
Florey Institute of Neuroscience and Mental Health, Parkville, Australia
Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Parkville, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen
School of Biosciences, University of Melbourne, Parkville, Australia
Univ Paris Diderot, Sorbonne Paris Cité, INSERM UMR1141, Paris, France
Issue Date: Dec-2018
EDate: 2018-12
Citation: Neurology. Genetics 2018; 4(6): e297
Abstract: To examine the genotype to phenotype connection in glucose transporter type 1 (GLUT1) deficiency and whether a simple functional assay can predict disease outcome from genetic sequence alone. GLUT1 deficiency, due to mutations in SLC2A1, causes a wide range of epilepsies. One possible mechanism for this is variable impact of mutations on GLUT1 function. To test this, we measured glucose transport by GLUT1 variants identified in population controls and patients with mild to severe epilepsies. Controls were reference sequence from the NCBI and 4 population missense variants chosen from public reference control databases. Nine variants associated with epilepsies or movement disorders, with normal intellect in all individuals, formed the mild group. The severe group included 5 missense variants associated with classical GLUT1 encephalopathy. GLUT1 variants were expressed in Xenopus laevis oocytes, and glucose uptake was measured to determine kinetics (Vmax) and affinity (Km). Disease severity inversely correlated with rate of glucose transport between control (Vmax = 28 ± 5), mild (Vmax = 16 ± 3), and severe (Vmax = 3 ± 1) groups, respectively. Affinities of glucose binding in control (Km = 55 ± 18) and mild (Km = 43 ± 10) groups were not significantly different, whereas affinity was indeterminate in the severe group because of low transport rates. Simplified analysis of glucose transport at high concentration (100 mM) was equally effective at separating the groups. Disease severity can be partly explained by the extent of GLUT1 dysfunction. This simple Xenopus oocyte assay complements genetic and clinical assessments. In prenatal diagnosis, this simple oocyte glucose uptake assay could be useful because standard clinical assessments are not available.
URI: http://ahro.austin.org.au/austinjspui/handle/1/20048
DOI: 10.1212/NXG.0000000000000297
ORCID: 0000-0003-2739-0515
0000-0003-4580-841X
0000-0002-2311-2174
PubMed URL: 30588498
ISSN: 2376-7839
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.